Combination Diagnostics: Adding Blood-Based ctDNA Screening to Low-Dose CT Imaging for Early Detection of Lung Cancer.

IF 29.7 1区医学 Q1 ONCOLOGY

Cancer discovery Pub Date : 2024-11-01 DOI:10.1158/2159-8290.CD-24-1195

Daniel A Haber, Steven J Skates

引用次数: 0

Abstract

Annual low-dose CT screening of individuals with a smoking history identifies early curable lung tumors and reduces cancer mortality by 20%, yet only a minority of eligible patients undergo such monitoring. Mazzone and colleagues apply a blood-based cfDNA fragmentomic assay as a high-sensitivity/low-specificity pre-screen to help stratify individuals who may benefit most from more definitive low-dose CT imaging. See related article by Mazzone et al., p. 2224.

查看原文本刊更多论文

联合诊断：在低剂量 CT 成像中加入基于血液的 ctDNA 筛查以早期检测肺癌。

每年对有吸烟史的人进行低剂量 CT 筛查可以发现早期可治愈的肺部肿瘤，并将癌症死亡率降低 20%，但只有少数符合条件的患者接受了这种监测。Mazzone 及其同事将基于血液的 cfDNA 片段组测定作为一种高灵敏度/低特异性的预筛查方法，帮助对可能从更明确的低剂量 CT 成像中获益最多的人进行分层。请参阅 Mazzone 等人的相关文章，第 2224 页。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer discovery ONCOLOGY-

CiteScore

22.90

自引率

1.40%

发文量

838

审稿时长

6-12 weeks

期刊介绍： Cancer Discovery publishes high-impact, peer-reviewed articles detailing significant advances in both research and clinical trials. Serving as a premier cancer information resource, the journal also features Review Articles, Perspectives, Commentaries, News stories, and Research Watch summaries to keep readers abreast of the latest findings in the field. Covering a wide range of topics, from laboratory research to clinical trials and epidemiologic studies, Cancer Discovery spans the entire spectrum of cancer research and medicine.